However, the evidence currently described is still insufficient for ICI to prolong the prognosis of EGFR-mutated NSCLC, and there is hope for the development of new agents such as ADC drugs and dual antibodies. This evidence concerns the gene EGFR and non-small cell lung carcinoma.